Indicators
Indicators
Value
Direction
MACD(12,26,9)
--
--
RSI(14)
--
--
STOCH(KDJ)(9,3,3)
--
--
ATR(14)
--
--
CCI(14)
--
--
Williams %R
--
--
TRIX(12,20)
--
--
StochRSI(14)
--
--
NuCana PLC
NCNAView Detailed Chart
0.660USD
0.000
Close 04/24, 16:00（ET）Quotes delayed by 15 min
3.75MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
1
analysts
HOLD
Current Rating
25.000
Target Price
2764.34%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
556
Total
5
Median
6
Average
Company name
Ratings
Analysts
NuCana PLC
NCNA
1
CRISPR Therapeutics AG
CRSP
29
Regeneron Pharmaceuticals Inc
REGN
28
Intellia Therapeutics Inc
NTLA
28
Moderna Inc
MRNA
27
Exact Sciences Corp
EXAS
27
1
2
3
...
111
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Neutral
Moving Average
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--
News
More news coming soon, stay tuned...
Company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Company codeNCNA
CompanyNuCana PLC
CEOMr. Hugh S. Griffith
Websitehttps://www.nucana.com/
